Pds biotech aligns with fda on phase 3 trial in hpv16-positive first-line recurrent or metastatic head and neck cancer

Company to initiate phase 3 versatile-003 trial in q4 2024 conference call today at 8:00 a.m. eastern time princeton, n.j.

PDSB Ratings Summary

PDSB Quant Ranking